Pricing
Login
Home
Charts
Search
Watchlist
Products

Bio Medica Laboratories Ltd

BMLL
₹160.70+10.83%20 Nov 2026
Reports
Pharma Formulations

Bio Medica Laboratories Ltd

BMLL
₹160.70
+10.83%
20 Nov 2026
Ask AI
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹202Cr
Close
Close Price
₹160.70
Industry
Industry
Pharma Formulations
PE
Price To Earnings
0.28
PS
Price To Sales
3.12
Revenue
Revenue
₹65Cr
Rev Gr TTM
Revenue Growth TTM
—
PAT Gr TTM
PAT Growth TTM
—

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2025Mar 2026Sep 2026
Revenue
RevenueCr
04322
Growth YoY
Revenue Growth YoY%
Expenses
ExpensesCr
02315
Operating Profit
Operating ProfitCr
0206
OPM
OPM%
45.628.4
Other Income
Other IncomeCr
001
Interest Expense
Interest ExpenseCr
021
Depreciation
DepreciationCr
011
PBT
PBTCr
0175
Tax
TaxCr
041
PAT
PATCr
0123
Growth YoY
PAT Growth YoY%
NPM
NPM%
27.615.7
EPS
EPS₹
0.012.9565.1
QuarterSep 2025Mar 2026Sep 2026
Revenue
RevenueCr
04322
Growth YoY
Revenue Growth YoY%
Expenses
ExpensesCr
02315
Operating Profit
Operating ProfitCr
0206
OPM
OPM%
45.628.4
Other Income
Other IncomeCr
001
Interest Expense
Interest ExpenseCr
021
Depreciation
DepreciationCr
011
PBT
PBTCr
0175
Tax
TaxCr
041
PAT
PATCr
0123
Growth YoY
PAT Growth YoY%
NPM
NPM%
27.615.7
EPS
EPS₹
0.012.9565.1

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2025Mar 2026TTM
Revenue
RevenueCr
384365
Growth
Revenue Growth%
12.4
Expenses
ExpensesCr
232339
Operating Profit
Operating ProfitCr
152026
OPM
OPM%
40.045.639.9
Other Income
Other IncomeCr
001
Interest Expense
Interest ExpenseCr
123
Depreciation
DepreciationCr
112
PBT
PBTCr
131623
Tax
TaxCr
346
PAT
PATCr
101215
Growth
PAT Growth%
21.4
NPM
NPM%
25.627.623.6
EPS
EPS₹
10.612.9578.0
Financial YearMar 2025Mar 2026TTM
Revenue
RevenueCr
384365
Growth
Revenue Growth%
12.4
Expenses
ExpensesCr
232339
Operating Profit
Operating ProfitCr
152026
OPM
OPM%
40.045.639.9
Other Income
Other IncomeCr
001
Interest Expense
Interest ExpenseCr
123
Depreciation
DepreciationCr
112
PBT
PBTCr
131623
Tax
TaxCr
346
PAT
PATCr
101215
Growth
PAT Growth%
21.4
NPM
NPM%
25.627.623.6
EPS
EPS₹
10.612.9578.0
Sales CAGR
1 Year12%
3 Years-
5 Years-
TTM-
EBITDA CAGR
1 Year28%
3 Years-
5 Years-
TTM-
PAT CAGR
1 Year21%
3 Years-
5 Years-
TTM-
Avg. ROCE
1 Year28%
3 Years-
5 Years-
TTM26%
CFO / EBITDA
1 Year-31%
3 Years-
5 Years-
TTM-

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2025Mar 2026Sep 2026
Equity Capital
Equity CapitalCr
9913
Reserves
ReservesCr
61757
Current Liabilities
Current LiabilitiesCr
1319
Non Current Liabilities
Non Current LiabilitiesCr
1134
Total Liabilities
Total LiabilitiesCr
3973111
Current Assets
Current AssetsCr
3155
Non Current Assets
Non Current AssetsCr
819
Total Assets
Total AssetsCr
3973111
Financial YearMar 2025Mar 2026Sep 2026
Equity Capital
Equity CapitalCr
9913
Reserves
ReservesCr
61757
Current Liabilities
Current LiabilitiesCr
1319
Non Current Liabilities
Non Current LiabilitiesCr
1134
Total Liabilities
Total LiabilitiesCr
3973111
Current Assets
Current AssetsCr
3155
Non Current Assets
Non Current AssetsCr
819
Total Assets
Total AssetsCr
3973111

Cash Flow

Consolidated
Standalone
Financial YearMar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
-5-6
Investing Cash Flow
Investing Cash FlowCr
0-2
Financing Cash Flow
Financing Cash FlowCr
58
Net Cash Flow
Net Cash FlowCr
00
Free Cash Flow
Free Cash FlowCr
-5-6
CFO To PAT
CFO To PAT%
-46.7-50.8
CFO To EBITDA
CFO To EBITDA%
-29.8-30.7
Financial YearMar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
-5-6
Investing Cash Flow
Investing Cash FlowCr
0-2
Financing Cash Flow
Financing Cash FlowCr
58
Net Cash Flow
Net Cash FlowCr
00
Free Cash Flow
Free Cash FlowCr
-5-6
CFO To PAT
CFO To PAT%
-46.7-50.8
CFO To EBITDA
CFO To EBITDA%
-29.8-30.7

Ratios

Consolidated
Standalone
Financial YearMar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
202
Price To Earnings
Price To Earnings
0.3
Price To Sales
Price To Sales
3.1
Price To Book
Price To Book
2.7
EV To EBITDA
EV To EBITDA
9.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
47.656.556.5
OPM
OPM%
40.045.639.9
NPM
NPM%
25.627.623.6
ROCE
ROCE%
48.227.825.7
ROE
ROE%
66.544.821.9
ROA
ROA%
25.316.213.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
202
Price To Earnings
Price To Earnings
0.3
Price To Sales
Price To Sales
3.1
Price To Book
Price To Book
2.7
EV To EBITDA
EV To EBITDA
9.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
47.656.556.5
OPM
OPM%
40.045.639.9
NPM
NPM%
25.627.623.6
ROCE
ROCE%
48.227.825.7
ROE
ROE%
66.544.821.9
ROA
ROA%
25.316.213.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Market CapitalizationMkt CapCr233232205202198177154
Close PriceClose₹404.00320.00167.10160.7067.20161.7018.54
IndustryIndustryPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma Formulations
Price To EarningsPE20.4528.9320.600.282.7233.4111.24
Price To SalesPS2.294.732.433.122.516.980.59
RevenueRevenueCr1014984657925259
Revenue Growth TTMRev Gr TTM%41.8%96.6%22.5%-14.9%3.4%50.8%
PAT Growth TTMPAT Gr TTM%16.6%83.2%33.6%421.4%-29.6%20.1%
Market CapitalizationMkt CapCr233232205202198177154
Close PriceClose₹404.00320.00167.10160.7067.20161.7018.54
IndustryIndustryPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma FormulationsPharma Formulations
Price To EarningsPE20.4528.9320.600.282.7233.4111.24
Price To SalesPS2.294.732.433.122.516.980.59
RevenueRevenueCr1014984657925259
Revenue Growth TTMRev Gr TTM%41.8%96.6%22.5%-14.9%3.4%50.8%
PAT Growth TTMPAT Gr TTM%16.6%83.2%33.6%421.4%-29.6%20.1%
Annual Reports
No recent documents found for this company.
Quarterly Reports
FY2026
Sep 26
Result
PPT
Transcript
Summary
Jun 26
Result
PPT
Transcript
Summary
Annual Reports
No recent documents found for this company.
Quarterly Reports
Sep 26
Result
PPT
Transcript
Summary
Jun 26
Result
PPT
Transcript
Summary
Load More
Interviews